Please use this identifier to cite or link to this item: https://www.arca.fiocruz.br/handle/icict/28202
Title: Treatment of hepatitis delta virus genotype 3 infection with peg-interferon and entecavir
Authors: Borzacov, Lourdes Maria Pinheiro.
Nicolete, Larissa Deadame de Figueiredo.
Souza, Luan Felipo Botelho.
Santos, Alcione Oliveira dos.
Vieira, Deusilene Souza.
Salcedo, Juan Miguel Villalobos.
Affilliation: Federal University of Rondônia. Research Center for Tropical Medicine of Rondônia. Porto Velho, RO, Brasil.
Federal University of Rondônia. Research Center for Tropical Medicine of Rondônia. Porto Velho, RO, Brasil.
Federal University of Rondônia. Research Center for Tropical Medicine of Rondônia. Porto Velho, RO, Brasil.
Federal University of Rondônia. Research Center for Tropical Medicine of Rondônia. Porto Velho, RO, Brasil.
Federal University of Rondônia. Research Center for Tropical Medicine of Rondônia. Porto Velho, RO, Brasil.
Federal University of Rondônia. Research Center for Tropical Medicine of Rondônia. Porto Velho, RO, Brasil.
Abstract: Objectives: Hepatitis delta virus (HDV) is recognized as the most pathogenic and infectious among the hepatotropic viruses. Studies on the treatment of HDV have predominantly included European patients and carriers of genotype 1 (HDV-1) in their clinical protocols. For the Amazon region, data show that infected individuals have mainly Native American ancestry and that >90% of HDV carriers have the genotype 3 (HDV-3). Thus combined therapy clinical protocols do not adequately address the treatment of these patients. Methods: A prospective, non-randomized study was conducted in which 22 patients received 180 mg of pegylated interferon alpha 2a (PEG-IFN) plus entecavir at a dose of 0.5 mg for 48 weeks, with a subsequent 24-week follow-up. Throughout treatment, the patients were monitored for biochemical responses and the kinetics of hepatitis B virus (HBV) and HDV viral loads. Results: Of the 22 patients treated, 15 presented normal alanine aminotransferase values at the end of treatment (p = 0.002). At week 24 of treatment, 86.4% of the patients did not present detectable HDV- RNA; at week 48, the rate of negative patients increased to >95% and remained the same after 6 months. With regard to HBV, only two patients (9%) still presented detectable HBV genetic material at the end of treatment, suggesting the effectiveness of combined therapy in combating the two viruses. Conclusions: These findings support the use of this effective therapeutic protocol for HDV-3 in patients of non-European ethnicity and suggest a possible ‘easy to treat’ variant when compared to HDV-1.
Keywords: HDV
Genotype 3
Treatment
PEG-IFN
Entecavir
Issue Date: 2016
Publisher: Elsevier
Citation: BORZACOV, L.M.P., et al. Treatment of hepatitis delta virus genotype 3 infection with peg-interferon and entecavir. International Journal of Infectious Diseases, v. 46, p. 82-88, 2016.
ISSN: 1201-9712
Copyright: open access
Appears in Collections:RO - Artigos de Periódicos

Files in This Item:
File Description SizeFormat 
Treatment of hepatitis delta virus genotype 3 infection with peg-interferon and entecavir.pdf625.16 kBAdobe PDFView/Open


FacebookTwitterDeliciousLinkedInGoogle BookmarksBibTex Format mendeley Endnote DiggMySpace

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.